INLYBEST-1 Tablets INLYBEST-1 contains Axitinib, a potent and selective second-generation tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3. By blocking ligand-induced receptor autophosphorylation, axitinib halts downstream endothelial cell signaling, proliferation, and survival, thereby inhibiting tumor angiogenesis and vascular permeability. It is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.